InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering
November 22, 2023

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study evaluating Berubicin. According to the announcement, the data showed the comparability of the patient demographics in the two arms of the study, and of the safety data for each therapeutic modality in treating recurrent Glioblastoma Multiforme (“GBM”). The data was presented in a poster presentation at the 28th annual Society of NeuroOncology meeting, which was held Nov. 15–19, 2023, in Vancouver, Canada. The poster, which was titled “A randomized, controlled trial of Berubicin vs. Lomustine after first-line therapy for glioblastoma multiforme (GBM): Interim Results,” is now available to view on the company’s website. Berubicin is CNS Pharmaceutical’s novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company’s CMO, Sandra Silberman, MD, PhD, presented the poster. “We continue to be encouraged by the preliminary safety data from Berubicin and are committed to moving this program forward,” said CNS Pharmaceuticals chief medical officer Dr. Sandra Silberman in the press release. “The preclinical and phase 1 clinical results give us reason to hope that Berubicin will ultimately be shown to provide a much-needed clinical benefit for GBM patients, and we remain on track to report the results of our interim analysis of efficacy data in December.”

To view the poster, visit https://ibn.fm/y2P9U

To view the full press release, visit https://ibn.fm/fuSUZ

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).